Menu
Back to Journals » OncoTargets and Therapy » Volume 5
Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
Authors Grünwald V, Merseburger A
Received 7 February 2012
Accepted for publication 20 April 2012
Published 18 June 2012 Volume 2012:5 Pages 111—117
DOI https://doi.org/10.2147/OTT.S23273
Review by Single anonymous peer review
Peer reviewer comments 2
Viktor Grünwald,1 Axel S Merseburger2
1Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 2Department of Urology, Hannover Medical School, Hannover, Germany
Abstract: The landscape of renal cell carcinoma (RCC) treatment has changed dramatically during recent years. Bevacizumab/interferon, sunitinib, sorafenib, temsirolimus, everolimus, and pazopanib have been proven effective in metastatic RCC. Axitinib is a novel tyrosine kinase inhibitor, which inhibits the vascular endothelial growth factor receptor (VEGFR) at subnanomolar level. Based on this extraordinary VEGFR inhibition, axitinib is considered a next-generation agent. The recent AXIS trial reported on axitinib's efficacy in second line treatment of RCC, which led to its recent approval in the USA. This review focuses on the clinical efficacy of axitinib in RCC patients.
Keywords: tyrosine kinase inhibitor, axitinib, tivozanib, renal cell carcinoma, VEGF
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.